
Caregivers reported itch, symptom, and QOL gains with roflumilast cream 0.05% in infants with AD; an FDA decision is due February 2027.
The request for a neurologic consultation sounded a bit out of the ordinary: "Please evaluate a 22-month-old with odd, shaking movements of the legs."






